South Africa’s pharmaceutical manufacturing crisis is growing as local producers lose government contracts and contend with rising costs. Stavros Nicolaou, chair of Pharmaceuticals Made in South Africa, says the Department of Health’s procurement policy is undermining the government’s localisation ambitions. He notes that officials award contracts to companies labelled as local suppliers. However, some companies import finished medicines rather than…
Tag: Localisation
-
Pharmaceutical Localisation Talks Target Investment And Supply
Senior government officials and top leaders of the pharmaceutical industry have agreed to pursue closer cooperation. South Africa seeks to boost local medicine production and enhance supply security. On 18 August, the two parties met in Pretoria to talk about the immediate pressures facing the sector. They discussed the longer-term measures needed to support pharmaceutical manufacturing. Professor Nicholas Crisp, who…
-
Aspen Insulin Approval Advances Local Health Solutions
Aspen Pharmacare has secured a landmark regulatory win after the South African Health Products Regulatory Authority (Sahpra) approved the commercial release of Aspen’s first locally manufactured human insulin batches. The products are cleared for sale in South Africa and other African markets, moving the project from planning into live supply for patients and health systems. Aspen produces the insulin at…
-
Pharma Giants Sidelined in R15.5bn HIV Drug Tender
The National Department of Health has awarded its latest three-year antiretroviral (ARV) tender, valued at R15.5 billion. This decision leaves several of South Africa’s largest domestic pharmaceutical manufacturers without a contract. The government’s procurement strategy sidelines pharma giants and sparks a fresh debate. This debate pits aggressive cost-saving measures against its stated goal of bolstering local industrial capacity. The tender…